441045-17-6

441045-17-6 structure

Name: Eribulin mesylate
Chemical Name: eribulin mesylate
CAS Number: 441045-17-6
Molecular Formula: C₄₁H₆₃NO₁₄S
Molecular Weight: 826.002
Catalog: Signaling Pathways Cell Cycle/DNA Damage Microtubule/Tubulin
Create Date: 2018-09-17 09:01:08
Modify Date: 2024-01-02 16:31:20
Eribulin mesylate is a microtubule targeting agent that is used in the treatment of metastatic breast cancer. It inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

Name	eribulin mesylate
Synonyms	UNII-AV9U0660CW E7389 Halaven (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,35R,36S)-20-[(2S)-3-Amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1.1.1.1.0.0.0]hentetracontan-24-one methanesulfonate (1:1) Eribulin mesylate

Description	Eribulin mesylate is a microtubule targeting agent that is used in the treatment of metastatic breast cancer. It inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin Research Areas >> Cancer
References	[1]. Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7(7): p. 2003-11. [2]. Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49(6): p. 1331-7. [3]. Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71(2): p. 496-505.

Hazard Codes	Xi